Expertise in
13
conditions

Marco Ruggeri

Vicenza, IT 
Expertise in
13
conditions
Vicenza, IT 

Overview

Marco Ruggeri practices practicing medicine in Vicenza, Italy.

Mr. Ruggeri is highly rated in 13 conditions, according to our data. His clinical expertise encompasses Essential Thrombocythemia, Polycythemia Vera, Adult Immune Thrombocytopenia, Splenectomy, and Bone Marrow Transplant.

He is actively involved in clinical research, co-authoring 81 peer reviewed articles and participating in 6 clinical trials.

Gender

Male

Locations

Vicenza, Italy
Other Locations
Ravenna, Italy
Florence, 50134, Italy

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

Myeloproliferative Neoplasms (MPN) and COVID-19
Myeloproliferative Neoplasms (MPN) and COVID-19
Enrollment Status: Completed
Publish Date: September 15, 2025
CLinical Decision-making, Prognosis, quAlity of Life and Satisfaction With caRe in patIents With Relapsed/refracTory Multiple mYeloma (CLARITY)
CLinical Decision-making, Prognosis, quAlity of Life and Satisfaction With caRe in patIents With Relapsed/refracTory Multiple mYeloma (CLARITY)
Enrollment Status: Active_not_recruiting
Publish Date: June 12, 2025
Intervention Type: Other
Long-term Study Evaluating the Effect of Givinostat in Patients With JAK2V617F Positive Chronic Myeloproliferative Neoplasms
Long-term Study Evaluating the Effect of Givinostat in Patients With JAK2V617F Positive Chronic Myeloproliferative Neoplasms
Enrollment Status: Active_not_recruiting
Publish Date: April 30, 2025
Intervention Type: Drug
Study Drug: Givinostat
Study Phase: Phase 2
The Benefit/Risk Profile of Pegylated Proline-Interferon Alpha-2b (AOP2014) Added to the Best Available Strategy Based on Phlebotomies in Low-risk Patients With Polycythemia Vera (PV). The Low-PV Randomized Trial
The Benefit/Risk Profile of Pegylated Proline-Interferon Alpha-2b (AOP2014) Added to the Best Available Strategy Based on Phlebotomies in Low-risk Patients With Polycythemia Vera (PV). The Low-PV Randomized Trial
Enrollment Status: Completed
Publish Date: September 19, 2024
Intervention Type: Drug, Procedure
Study Drugs: AOP2014, Acetylsalicylic acid
Study Phase: Phase 2
Eltrombopag as Second Line Therapy in Adult Patients With Primary Immune Thrombocytopenia (ESTIT Study) in an Attempt to Achieve Long-term Remission: a Single Arm Multicenter Phase II Clinical and Biological Study
Eltrombopag as Second Line Therapy in Adult Patients With Primary Immune Thrombocytopenia (ESTIT Study) in an Attempt to Achieve Long-term Remission: a Single Arm Multicenter Phase II Clinical and Biological Study
Enrollment Status: Completed
Publish Date: August 16, 2021
Intervention Type: Drug
Study Phase: Phase 2
A Two-part Study Top Assess the Safety and Preliminary Efficacy of Givinostat in Patients With JAK2V617F Positive Polycythemia Vera
A Two-part Study Top Assess the Safety and Preliminary Efficacy of Givinostat in Patients With JAK2V617F Positive Polycythemia Vera
Enrollment Status: Completed
Publish Date: July 30, 2019
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
View 5 Less Clinical Trials

81 Total Publications

Genomic profiling for decision-making in post-polycythemia vera and post-essential thrombocythemia myelofibrosis.
Genomic profiling for decision-making in post-polycythemia vera and post-essential thrombocythemia myelofibrosis.
Journal: Blood
Published: August 26, 2025

Frequently Asked Questions about Marco Ruggeri

Is Marco Ruggeri a top-rated expert for Essential Thrombocythemia?

MediFind is an objective health platform that identifies experts based on real-world data. Marco Ruggeri is classified as an Elite expert for Essential Thrombocythemia, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Marco Ruggeri participate in research or clinical trials?

Yes. Marco Ruggeri has published 81 articles and abstracts on conditions like Essential Thrombocythemia. You can view a list of Marco Ruggeri's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Ruggeri's expertise for a condition
ConditionClose
View All 8 Distinguished Conditions
View All 19 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile